EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

The utility of immunohistochemistry-based biomarkers in predicting the pathological complete response in early-stage triple-negative breast cancer

Chikako Funasaka, Takahiro Kogawa, Naoya Sakamoto, Shota Kusuhara, Takehiro Nakao, Hiromichi Nakajima, Chihiro Kondoh, Kenichi Harano, Nobuaki Matsubara, Ako Hosono, Yoichi Naito, Mototsugu Shimokawa und 6 weitere

Cancer Treatment and Research Communications · 2025

DOI: 10.1016/j.ctarc.2025.100941 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Treatment and Research Communications, 2025. Verfasst von Chikako Funasaka und 17 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Medical Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Japan; Departments of Experimental Thera…. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Biomarkers, Tumor, Immunohistochemistry, Lymphocytes, Tumor-Infiltrating. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: JSPS KAKENHI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple-negative breast cancer (TNBC) is a highly aggressive subtype of BC. A pathological complete response (pCR) to neoadjuvant chemotherapy is strongly associated with a favorable TNBC prognosis; however, established predictors of pCR, including tumor-infiltrating lymphocytes (TILs), are often not adequately reliable in the clinic. This study evaluated the utility of immunohistochemistry (IHC)-based markers and TILs in predicting pCR in early-stage TNBC. This study enrolled 61 women with stage I-III TNBC who were treated at our institution between January 2013 and December 2019. Pathological data were collected from electronic medical records, while IHC data were obtained from preoperative biopsy specimens. Fisher's test, multivariable logistic regression, and correlation analyses were used to identify biomarker candidates and their interactions. The majority of the patients had stage II or III invasive ductal TNBC. The pCR rate was 31 % (19/61). High TIL frequencies (≥ 40 %) and high Ki-67 (≥ 40 %) levels were associated with pCR. Among the patients with high TIL frequencies, AR-negative patients had a higher pCR rate than AR-positive patients (55.0 % versus 16.7 %; p = 0.71). Vimentin negativity correlated with high TIL frequencies (p = 0.02). High TIL frequencies and high Ki-67 levels were independently associated with an increased likelihood of achieving a pCR. The combination of high TIL frequencies and high Ki-67 levels was predictive of pCR in patients with primary TNBC, while AR and vimentin represent candidate markers that require further validation. Further studies should evaluate the performance of these markers in combination with other biomarkers and in the context of immune-checkpoint blockade.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsBiomarkers, TumorImmunohistochemistryLymphocytes, Tumor-InfiltratingHumansFemaleMiddle AgedAdultNeoadjuvant TherapyNeoplasm StagingAgedPrognosisRetrospective Studies

Stichwörter der Autor:innen

TILTriple-negative breast cancerneoadjuvant chemotherapy

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Departments of Medical Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Japan; Departments of Experimental Therapeutics, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kash…
  • Departments of Pathology and Clinical Laboratories, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Japan.
  • Departments of Medical Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Japan.
  • Departments of Experimental Therapeutics, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Japan.
  • Departments of Medical Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Japan; Departments of Pediatric Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, 27…
  • Department of Biostatistics, Yamaguchi University Graduate School of Medicine, 1-1-1, Minamikogushi, Ube City, Yamaguchi, 755-0046, Japan.

Förderung

  • JSPS KAKENHI

Zitieren

APA

Funasaka, C., Kogawa, T., Sakamoto, N., Kusuhara, S., Nakao, T., Nakajima, H., Kondoh, C., Harano, K., Matsubara, N., Hosono, A., Naito, Y., Shimokawa, M., Watanuki, R., Yamashita, Y., Yamauchi, C., Onishi, T., Ishii, G., & Mukohara, T. (2025). The utility of immunohistochemistry-based biomarkers in predicting the pathological complete response in early-stage triple-negative breast cancer. Cancer Treatment and Research Communications. https://doi.org/10.1016/j.ctarc.2025.100941

Vancouver

Funasaka C, Kogawa T, Sakamoto N, Kusuhara S, Nakao T, Nakajima H, et al. The utility of immunohistochemistry-based biomarkers in predicting the pathological complete response in early-stage triple-negative breast cancer. Cancer Treatment and Research Communications. 2025. doi:10.1016/j.ctarc.2025.100941

BibTeX
@article{Funasaka2025,
  author = {Funasaka, Chikako and Kogawa, Takahiro and Sakamoto, Naoya and Kusuhara, Shota and Nakao, Takehiro and Nakajima, Hiromichi and Kondoh, Chihiro and Harano, Kenichi and Matsubara, Nobuaki and Hosono, Ako and Naito, Yoichi and Shimokawa, Mototsugu and Watanuki, Rurina and Yamashita, Yuji and Yamauchi, Chisako and Onishi, Tatsuya and Ishii, Genichiro and Mukohara, Toru},
  title = {The utility of immunohistochemistry-based biomarkers in predicting the pathological complete response in early-stage triple-negative breast cancer},
  journal = {Cancer Treatment and Research Communications},
  year = {2025},
  doi = {10.1016/j.ctarc.2025.100941}
}
Kostenlos starten →